	US 12,290,496 B2
	Compounds for use in preventing or treating athlete overtraining
Kieran Clarke, Oxford (GB); and Peter Hespel, Leuven (BE)
Assigned to TDELTAS LIMITED, Thame (GB)
Appl. No. 17/282,594
Filed by TDELTAS LIMITED, Thame (GB)
PCT Filed Oct. 3, 2019, PCT No. PCT/GB2019/052797 § 371(c)(1), (2) Date Apr. 2, 2021, PCT Pub. No. WO2020/070506, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 1816196 (GB), filed on Oct. 4, 2018.
Prior Publication US 2021/0338612 A1, Nov. 4, 2021
Int. Cl. A61K 31/19 (2006.01); A61K 31/22 (2006.01); A61K 31/23 (2006.01); A61K 31/765 (2006.01); A61P 21/06 (2006.01)

CPC A61K 31/19 (2013.01) [A61K 31/22 (2013.01); A61K 31/23 (2013.01); A61K 31/765 (2013.01); A61P 21/06 (2018.01)]

17 Claims

1. A method of treating overtraining syndrome in a subject in need thereof, comprising administering to the subject

an ester of (R)-3-hydroxybutyrate or a pharmaceutically acceptable salt or solvate thereof.